GLP-1 Agonists Show Significant Weight Loss in Adults Without Diabetes

Obesity is a global health crisis associated with numerous comorbidities like cardiovascular disease, type 2 diabetes, and certain cancers. While Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs) are well-established for managing type 2 diabetes and have shown promise for weight loss, a comprehensive synthesis of their efficacy and safety specifically in adults without diabetes was needed. This systematic review addresses the knowledge gap regarding the overall effectiveness and safety profile of GLP-1 RAs for weight management in non-diabetic individuals.

The meta-analysis revealed a highly significant and consistent weight loss benefit with GLP-1 RAs compared to placebo. Participants treated with GLP-1 RAs achieved a mean additional weight loss of 12.5 kg (or 12.8% of body weight) compared to control groups. Specifically, semaglutide 2.4 mg weekly demonstrated the most pronounced effect, leading to an average 15.3% body weight reduction over 68 weeks, significantly greater than the 2.5% reduction seen with placebo. The most important finding was that GLP-1 RAs consistently led to a 10-15% greater body weight reduction compared to placebo, with a favorable safety profile dominated by transient gastrointestinal side effects. Common adverse events were primarily gastrointestinal, including nausea (30-50% incidence), diarrhea (15-25%), and vomiting (10-20%), which were generally mild to moderate and decreased over time. Serious adverse events were rare, and discontinuation rates due to adverse events were typically 2-3 times higher in the GLP-1 RA groups but remained acceptable.